| Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study T Thepen, EG Langeveld-Wildschut, IC Bihari, DF van Wichen, ... Journal of Allergy and Clinical Immunology 97 (3), 828-837, 1996 | 484 | 1996 |
| Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic … S Ferrari, F Scheiflinger, M Rieger, G Mudde, M Wolf, P Coppo, JP Girma, ... Blood 109 (7), 2815-2822, 2007 | 310 | 2007 |
| Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase Cγ2 that specifically increases external Ca2+ entry P Yu, R Constien, N Dear, M Katan, P Hanke, TD Bunney, S Kunder, ... Immunity 22 (4), 451-465, 2005 | 196 | 2005 |
| Consequences of IgE/CD23-mediated antigen presentation in allergy GC Mudde, R Bheekha, CAFM Bruijnzeel-Koomen Immunology today 16 (8), 380-383, 1995 | 154 | 1995 |
| Skin disease‐related T cells bind to endothelial selectins: expression of cutaneous lymphocyte antigen (CLA) predicts E‐selectin but not P‐selectin binding H Rossiter, F Van Reijsen, GC Mudde, F Kalthoff, AFM Carla, LJ Picker, ... European journal of immunology 24 (1), 205-210, 1994 | 147 | 1994 |
| Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering M Schuster, P Umana, C Ferrara, P Brünker, C Gerdes, G Waxenecker, ... Cancer Research 65 (17), 7934-7941, 2005 | 137 | 2005 |
| Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions EG Langeveld-Wildschut, PLB Bruijnzeel, GC Mudde, C Versluisa, ... Journal of allergy and clinical immunology 105 (5), 1008-1016, 2000 | 125 | 2000 |
| Evaluation of variables influencing the outcome of the atopy patch test EG Langeveld-Wildschut, AMW van Mariona, T Thepen, GC Mudde, ... Journal of allergy and clinical immunology 96 (1), 66-73, 1995 | 119 | 1995 |
| In vivo glyco‐engineered antibody with improved lytic potential produced by an innovative non‐mammalian expression system M Schuster, W Jost, GC Mudde, S Wiederkum, C Schwager, E Janzek, ... Biotechnology Journal: Healthcare Nutrition Technology 2 (6), 700-708, 2007 | 101 | 2007 |
| Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors M Klinger, H Farhan, H Just, H Drobny, G Himmler, H Loibner, GC Mudde, ... Cancer Research 64 (3), 1087-1093, 2004 | 79 | 2004 |
| Antigen focusing by specific monomeric immunoglobulin E bound to CD23 on Epstein-Barr virus-transformed B cells LF Santamaria, R Bheekha, FC van Reijsen, MTP Soler, M Suter, ... Human immunology 37 (1), 23-30, 1993 | 71 | 1993 |
| Long-lived Th2 clones specific for seasonal and perennial allergens can be detected in blood and skin by their TCR-hypervariable regions B Bohle, H Schwihla, HZ Hu, R Friedl-Hajek, S Sowka, F Ferreira, ... The Journal of Immunology 160 (4), 2022-2027, 1998 | 69 | 1998 |
| IgE-mediated antigen presentation. GC Mudde, R Bheekha, C Bruijnzeel-Koomen Allergy 50 (3), 1995 | 63 | 1995 |
| Selective targeting of a disease-related conformational isoform of macrophage migration inhibitory factor ameliorates inflammatory conditions M Thiele, RJ Kerschbaumer, FWK Tam, D Völkel, P Douillard, A Schinagl, ... The Journal of Immunology 195 (5), 2343-2352, 2015 | 51 | 2015 |
| IgE-positive Langerhans cells and Th2 allergen-specific T cells in atopic dermatitis GC Mudde, FC van Reijsen, CAFM Bruijnzeel-Koomen Journal of investigative dermatology 99 (5), S103, 1992 | 43 | 1992 |
| Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen H Farhan, C Schuster, M Klinger, E Weisz, G Waxenecker, M Schuster, ... Journal of Pharmacology and Experimental Therapeutics 319 (3), 1459-1466, 2006 | 40 | 2006 |
| Antigen presentation in allergic sensitization GC Mudde, IG Reischl, N Corvaïa, A Hren, EVAM POELLABAUER Immunology and cell biology 74 (2), 167-173, 1996 | 38 | 1996 |
| A HER2-specific modified Fc fragment (Fcab) induces antitumor effects through degradation of HER2 and apoptosis KM Leung, S Batey, R Rowlands, SJ Isaac, P Jones, V Drewett, ... Molecular Therapy 23 (11), 1722-1733, 2015 | 37 | 2015 |
| MDP (Lysyl) GDP, a nontoxic muramyl dipeptide derivative, inhibits cytokine production by activated macrophages and protects mice from phorbol ester-and oxazolone-induced … M Zunic, GC Mudde, JG Meingassner, C Lam, GM Bahr Journal of investigative dermatology 111 (1), 77-82, 1998 | 29 | 1998 |
| Cytotoxic immunoglobulin G Himmler, G Mudde, A Bauer, G Redl, M Woisetschlager US Patent 8,859,738, 2014 | 23 | 2014 |
